(Q46914336)

26 December 2017

title

Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber (English)

1 reference

26 December 2017

1 reference

1 reference

Petra Stuebner

1

1 reference

26 December 2017

Friedrich Horak

2

1 reference

26 December 2017

René Zieglmayer

3

1 reference

26 December 2017

Eva Arnáiz

4

1 reference

26 December 2017

Chiara Leuratti

5

1 reference

26 December 2017

Iñaki Pérez

6

1 reference

26 December 2017

Iñaki Izquierdo

7

1 reference

26 December 2017

publication date

1 January 2006

1 reference

26 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

26 December 2017

volume

96

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

37-44

1 reference

26 December 2017

Allergic rhinitis: past, present and the future

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Antihistamines in late-phase clinical development for allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Allergic rhinitis: broader disease effects and implications for management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Validation of the classification of ARIA (allergic rhinitis and its impact on asthma).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Molecular and cellular mechanisms of allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Allergic rhinitis: not purely a histamine-related disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Sample size calculations for clinical pharmacology studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Impact and modulation of nasal obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961038-1

7 January 2021

10.1016/S1081-1206(10)61038-1

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017